{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06503679",
            "orgStudyIdInfo": {
                "id": "27110"
            },
            "secondaryIdInfos": [
                {
                    "id": "J5C-MC-FOAF",
                    "type": "OTHER",
                    "domain": "DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company"
                }
            ],
            "organization": {
                "fullName": "DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Cytochrome P450 3A4 and 2C8 Substrates in Healthy Participants",
            "officialTitle": "A Phase 1, Single-center, Open-label, Fixed-sequence, Crossover Study to Evaluate the Effect of LY4100511 (DC-853) on the Single-dose Pharmacokinetics of Cytochrome P450 Enzyme Substrates in Healthy Participants",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-drug-drug-interaction-study-evaluating-the-perpetrator-potential-of-dc-on-cytochrome-and-substrates-in-healthy-participants"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-10",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-07-10",
            "studyFirstSubmitQcDate": "2024-07-10",
            "studyFirstPostDateStruct": {
                "date": "2024-07-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 (DC-853) when administered alone or in the presence of cytochrome P450 substrates in healthy participants."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy"
            ],
            "keywords": [
                "LY4100511",
                "DC-853"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 32,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "LY4100511 Dose 1 + Midazolam + Repaglinide (Cohort 1)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive an oral dose 1 of LY4100511 and single dose of midazolam and repaglinide.",
                    "interventionNames": [
                        "Drug: LY4100511 (DC-853) Dose 1",
                        "Drug: Midazolam",
                        "Drug: Repaglinide"
                    ]
                },
                {
                    "label": "LY4100511 Dose 2 + Midazolam + Repaglinide (Cohort 2)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive up to an oral dose 2 of LY4100511 and single dose of midazolam and repaglinide. Dosing will not proceed until a satisfactory review of the safety and tolerability data from lower dose level is performed.",
                    "interventionNames": [
                        "Drug: LY4100511 (DC-853) Dose 2",
                        "Drug: Midazolam",
                        "Drug: Repaglinide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "LY4100511 (DC-853) Dose 1",
                    "description": "Administered orally",
                    "armGroupLabels": [
                        "LY4100511 Dose 1 + Midazolam + Repaglinide (Cohort 1)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "LY4100511 (DC-853) Dose 2",
                    "description": "Administered orally",
                    "armGroupLabels": [
                        "LY4100511 Dose 2 + Midazolam + Repaglinide (Cohort 2)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Midazolam",
                    "description": "Administered orally",
                    "armGroupLabels": [
                        "LY4100511 Dose 1 + Midazolam + Repaglinide (Cohort 1)",
                        "LY4100511 Dose 2 + Midazolam + Repaglinide (Cohort 2)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Repaglinide",
                    "description": "Administered orally",
                    "armGroupLabels": [
                        "LY4100511 Dose 1 + Midazolam + Repaglinide (Cohort 1)",
                        "LY4100511 Dose 2 + Midazolam + Repaglinide (Cohort 2)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-\u221e]) of Midazolam and 1-Hydroxymidazolam and Repaglinide",
                    "description": "PK parameters of midazolam and 1-hydroxymidazolam and repaglinide in the absence or presence of steady-state LY4100511",
                    "timeFrame": "Day 1 and Day 9: Predose, Up to 48 Hours Post Dose"
                },
                {
                    "measure": "PK: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of Midazolam and 1-Hydroxymidazolam and Repaglinide",
                    "description": "PK parameters of midazolam and 1-hydroxymidazolam and repaglinide in the absence or presence of steady-state LY4100511",
                    "timeFrame": "Day 1 and Day 9: Predose, Up to 48 Hours Post Dose"
                },
                {
                    "measure": "PK: Maximum Observed Concentration (Cmax) of Midazolam and 1-Hydroxymidazolam and Repaglinide",
                    "description": "PK parameters of midazolam and 1-hydroxymidazolam and repaglinide in the absence or presence of steady-state LY4100511",
                    "timeFrame": "Day 1 and Day 9: Predose, Up to 48 Hours Post Dose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Females must be of childbearing potential\n* Males must agree to use contraception\n* Have body mass index (BMI) between 18.0 and 32.0 kilogram/square meter (kg/m\u00b2), inclusive, and a body weight of greater than or equal to 50 kg.\n* In good health, as determined by no clinically significant findings from medical history, 12-lead ECG and vital signs measurements, and clincial laboratory evaluations (congentical nonhemolytic hyperbilirubinemia) at screening and check-in, anf from the physical examination at check-in as assessed by the investigator.\n\nExclusion Criteria:\n\n* Have a 12-lead ECG abnormality that, in the opinion of the investigator,\n\n  * increases the risks associated with participating in the study\n  * may confound ECG data analysis\n  * a QTCF \\>450 msec for males, or \\>470 msec for females\n\n    * short PR interval \\<120 msec or PR interval \\>220 msec\n    * second or third degree atrioventricular block\n    * intraventricular conduction delay with QRS \\>120 msec\n    * complete right bundle branch block\n    * left bundle branch block, or\n    * Wolff Parkinson-White syndrome.\n* Have had current or recent acute infection\n* Show evidence of active or latent tuberculosis (TB)\n* Had any surgical procedures within 12 weeks prior to screening or any planned surgical procedure scheduled to occur during the study.\n* Have a history or presence of multiple or severe allergies, or an anaphylactic reaction to prescription or non prescription drugs.\n* Are immunocompromised\n* Presence of active suicidal ideation or positive suicide behavior using baseline/screening version of the C-SSRS",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "55 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "This is a single site in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or",
                    "role": "CONTACT",
                    "phone": "3176154559",
                    "email": "ClinicalTrials.gov@lilly.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",
                    "affiliation": "Eli Lilly and Company",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Fortrea Clinical Research Unit Inc.",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75247",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Abiodun Adefurin",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000072379",
                    "term": "Repaglinide"
                },
                {
                    "id": "D000008874",
                    "term": "Midazolam"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000759",
                    "term": "Adjuvants, Anesthesia"
                },
                {
                    "id": "D000006993",
                    "term": "Hypnotics and Sedatives"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000014151",
                    "term": "Anti-Anxiety Agents"
                },
                {
                    "id": "D000014149",
                    "term": "Tranquilizing Agents"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000018686",
                    "term": "Anesthetics, Intravenous"
                },
                {
                    "id": "D000018681",
                    "term": "Anesthetics, General"
                },
                {
                    "id": "D000000777",
                    "term": "Anesthetics"
                },
                {
                    "id": "D000018757",
                    "term": "GABA Modulators"
                },
                {
                    "id": "D000018682",
                    "term": "GABA Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M354161",
                    "name": "Repaglinide",
                    "asFound": "Full thickness",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11845",
                    "name": "Midazolam",
                    "asFound": "Course",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4107",
                    "name": "Anesthetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M4089",
                    "name": "Adjuvants, Anesthesia",
                    "relevance": "LOW"
                },
                {
                    "id": "M10043",
                    "name": "Hypnotics and Sedatives",
                    "relevance": "LOW"
                },
                {
                    "id": "M16905",
                    "name": "Anti-Anxiety Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M20766",
                    "name": "Anesthetics, Intravenous",
                    "relevance": "LOW"
                },
                {
                    "id": "M20761",
                    "name": "Anesthetics, General",
                    "relevance": "LOW"
                },
                {
                    "id": "M20827",
                    "name": "GABA Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AdjAn",
                    "name": "Adjuvants, Anesthesia"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                }
            ]
        }
    },
    "hasResults": false
}